ArticleJTCVS open2026
Cost-effectiveness of multiarterial versus single-arterial grafting in coronary artery bypass surgery.
Article in JTCVS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the cost-effectiveness of multiarterial grafting (MAG) compared with single artery grafting (SAG) using institutional outcomes and a linked perioperative-chronic Markov model. Methods: This was a retrospective cohort study of 3583 adults undergoing isolated coronary artery bypass grafting between 2008 and 2022 at 2 tertiary hospital centers. Operative and perioperative data were obtained from the institutional Society of Thoracic Surgeons database. Propensity score overlap weighting was used to balance baseline covariates. A 2-phase (30-day perioperative and 10-year chronic) Markov state-transition model, informed by weighted institutional outcomes and supplemented with national Society of Thoracic Surgeons and Centers for Medicare & Medicaid Services data, was used to estimate long-term costs and quality-adjusted life years. Results: Among 3583 patients at 2 academic centers, MAG was associated with similar operative mortality and morbidity compared with SAG. In a linked perioperative-chronic Markov model, MAG yielded greater quality-adjusted survival (+0.241 quality-adjusted life-years) and lower 10-year discounted costs (-$7755 per patient). Sensitivity analyses demonstrated that MAG was not consistently cost-effective in the perioperative period but was robustly dominant in the chronic phase, with long-term results stable across a wide range of cost assumptions. Conclusions: MAG was associated with comparable perioperative outcomes but improved quality-adjusted survival and lower long-term costs compared with SAG. Broader adoption of MAG could reduce health care expenditures while improving population health by addressing barriers to MAG use, particularly in women, minority patients, and socially vulnerable populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.